Roche Diagnostics: FDA 510(k) clearances across all its applicant names

FDA lists 1,338 510(k) clearances, 53 PMA and 10 De Novo decisions across the 25 applicant names Caduvo groups under Roche Diagnostics, first 1976, latest 2026. Median 510(k) review time across these names: 65 days. Since 2017 the median was 169 days, against 160 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.

510(k) clearances per year

YearClearancesMedian review days
201221165
201318136
20142185
201513133
201613148
201716123
201815132
2019870
20207146
202110152
202219209
202314233
20246266
202518176
202620171

The 25 FDA applicant names in this group

Applicant name510(k) clearancesPMADe NovoYears
Roche Diagnostics Corp.4541541999–2026
Boehringer Mannheim Corp.340101976–1999
Roche Diagnostic Systems, Inc.296001983–1999
Roche Molecular Systems, Inc.521531993–2026
Hoffmann-La Roche, Inc.49001976–1985
Ventana Medical Systems, Inc.461331992–2024
Disetronic Medical Systems17001991–2001
Roche Diagnostics Operations (Rdo)14002014–2020
Disetronic Medical Systems AG12002000–2010
Roche Analytical Instruments, Inc.11001980–1980
Roche Diabetes Care, Inc.10002015–2023
Genmark Diagnostics, Incorporated9002011–2026
Roche Diagnostics Operations7202012–2025
Roche Diagnostics GmbH5201998–2026
Boehringer Mannheim Italia Spa3001994–1996
Roche Diagnostics/Boehringer Mannheim GmbH3001998–1999
Roche2102011–2012
Roche Diabetes Care GmbH2002023–2023
Roche Professional Diagnostics2002010–2015
Roche Diabetes Care AG1002012–2012
Roche Diagnostics Hematology, Inc.1002018–2018
Ventana, Inc.1001999–1999
Ventana Medical Sytems, Inc.1002011–2011
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)030—
Roche Molecular System, Inc.010—

Review time against the same product codes

Since 2017, 510(k)s cleared under these names took a median 169 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 160 days.

Top product codes

Product codeDeviceSubmissions510(k) clearances
JJXSingle (Specified) Analyte Controls (Assayed And Unassayed)8787
JJYMulti-Analyte Controls, All Kinds (Assayed)4242
JIXCalibrator, Multi-Analyte Mixture3131
DKZEnzyme Immunoassay, Amphetamine2727
NBWSystem, Test, Blood Glucose, Over The Counter2424
CGAGlucose Oxidase, Glucose2222
LFRGlucose Dehydrogenase, Glucose2222
JITCalibrator, Secondary2020
DKBCalibrators, Drug Mixture1919
DIFDrug Mixture Control Materials1818

Plus 343 more product codes.

Review panels

Most recent Roche Diagnostics 510(k) clearances

510(k)DeviceApplicant nameProduct codeDecision dateReview days
K262938cobas eplex respiratory pathogen panel 3Genmark Diagnostics, IncorporatedQOF2026-10-3070
K260233Elecsys EBV IgMRoche Diagnostics Corp.LJN2026-10-02249
K260232Elecsys EBV VCA IgGRoche Diagnostics Corp.LSE2026-10-02249
K260221Elecsys EBV EBNA IgGRoche Diagnostics Corp.LSE2026-10-02249
K260047cobas Strep A Nucleic acid test for use on the cobas Liat System (07341911190); cobas Strep A Quality Control Kit (07402678190)Roche Molecular Systems, Inc.PGX2026-08-28233
K260045cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System (07454945190); cobas® Cdiff Positive and Negative Control Kit for use on the cobas® Liat® System (07454970190)Roche Molecular Systems, Inc.OZN2026-08-28233
K261686Elecsys Phospho-Tau (217P) PlasmaRoche Diagnostics Corp.SET2026-08-1990
K260021cobas® BV/CVRoche Molecular Systems, Inc.PQA2026-07-16192
K260917cobas CT/NG for use on the cobas 5800/6800/8800 systems; cobas TV/MG for use on the cobas 5800/6800/8800 systemsRoche Molecular Systems, Inc.QEP2026-07-08111
K252323cobas pulse blood glucose monitoring systemRoche Diagnostics Corp.PZI2026-06-12322

1,328 earlier clearances. See the full list in Caduvo.

PMA and De Novo decisions

NumberPathwayDeviceDecision date
DEN260027De NovoQuantitative Hepatitis B Surface Antigen2026-10-20
P250031PMAVENTANA PTEN (SP218) RxDx Assay2026-06-12
P240037PMAVENTANA MET (SP44) RxDx Assay2025-05-14
DEN240025De NovoKappa And Lambda Immunoglobulin Light Chain In Situ Hybridization Mrna Probe Detection Kit2024-12-05
P230018PMAVENTANA CLDN18 (43-14A) RxDx Assay2024-10-18

Recalls

576 product recalls in 269 recall events under these names; 19 initiated in the last five years.

14 product recalls in 2 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 0 initiated in the last five years. Most often: Roche Insulin Delivery Systems Inc. (13), Cardinal Health Inc. (1).

These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.

Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.

Device clinical trials

ClinicalTrials.gov lists 66 device studies (13 active or recruiting) with an industry lead sponsor under the 1 sponsor name below. Most recent:

Lead sponsor name on ClinicalTrials.govDevice studies
Hoffmann-La Roche66

Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.

How this group is built

Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.

Boehringer Mannheim (1998), Disetronic (2003), Ventana Medical Systems (2008), GenMark (2021). Includes filings made before each acquisition. HOFFMANN-LA ROCHE is the parent's own 1976–1985 filings. Left out: Roche Medical Electronics (1970s monitoring business, later sold) and two small names with unclear history.

Sources

Frequently asked questions

How many FDA 510(k) clearances are listed across Roche Diagnostics's applicant names?

FDA lists 1,338 510(k) clearances, 53 PMA and 10 De Novo decisions across the 25 applicant names Caduvo groups under Roche Diagnostics, first 1976, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.

Which FDA applicant names does Roche Diagnostics file under?

The names with the most 510(k) clearances in this group are Roche Diagnostics Corp. (454); Boehringer Mannheim Corp. (340); Roche Diagnostic Systems, Inc. (296); Roche Molecular Systems, Inc. (52); Hoffmann-La Roche, Inc. (49). The full list of 25 names is on this page.

How long does FDA take to clear Roche Diagnostics 510(k)s?

The median time from FDA receipt to decision across 510(k)s cleared under these names is 65 days. Since 2017 the median was 169 days, against 160 days for all cleared 510(k)s in the same product codes.

Does the Roche Diagnostics count include acquired companies?

Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.

How many device clinical trials does Roche Diagnostics sponsor?

ClinicalTrials.gov lists 66 device studies (13 active or recruiting) with an industry lead sponsor under 1 sponsor name Caduvo groups under Roche Diagnostics. ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.

Next steps

Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.

All parent companies · FDA device companies by applicant name · FDA product code lookup